Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc

11 Feb 2013

• By Stacy Lawrence, Jessica Merrill, and Sten Stovall

Related Content

Biogen/Elan Seek First-Line Claim For <em>Tysabri</em> In JCV-Negative MS Patients

16 Jan 2013

Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera

28 Jan 2013

Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More

28 Jan 2013

Galenica Will Leverage Aspreva Acquisition To Strengthen Specialty Pharma Group

19 Oct 2007

Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO

05 Jul 2010

Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri

06 Feb 2013

The Medicines Co. Enters PCSK9 Race With Alnylam Deal

04 Feb 2013

Related Companies

Bausch Health Companies Inc.

Bristol Myers Squibb Company

Biogen, Inc.

Elan Corporation

Amgen, Inc.

Gilead Sciences, Inc.

Pfizer Inc.

Johnson & Johnson

Merck & Co., Inc.

The Medicines Company

Alnylam Pharmaceuticals Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Ipsen SA

Cangene Corporation

Baxter International Inc.

Aurinia Pharmaceuticals Inc.

CSL Vifor

Additional Topics

Deals BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.